A Connecticut law that took effect July 1 expands eligibility for the Department of Mental Health and Addiction Services’ psychedelic-assisted therapy pilot program at New Haven, Conn.-based Yale University.
The pilot program was launched in 2022 through a partnership between DMHAS and Yale School of Medicine to provide MDMA- or psilocybin-assisted therapy, according to a Joint Favorable Report from the state’s Public Health Committee.
Here are three things to know:
- The law allows Connecticut residents age 18 and older who meet clinical eligibility criteria established by the institutional review board at Yale School of Medicine, which administers the program, to participate.
- Previously, the pilot program was limited to veterans, retired first responders and direct healthcare workers. Participants must receive MDMA or psilocybin-assisted therapy as part of a research program approved by the FDA.
- The act also eliminated a requirement that DMHAS end the pilot program if the FDA approves MDMA and psilocybin for medical use.
At the Becker's Fall Behavioral Health Summit, taking place November 4–5 in Chicago, behavioral health leaders and executives will explore strategies for expanding access to care, integrating services, addressing workforce challenges and leveraging innovation to improve outcomes across the behavioral health continuum. Apply for complimentary registration now.
